Skip to main content
SpringerLink
Log in

Bei häufigen Kopfschmerzen an Migräne denken

Migräne - Diagnostik und Prophylaxe

Migraine - diagnosis and prophylaxis

  • FB_CME
  • Published:
MMW - Fortschritte der Medizin Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Olesen J et al. The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38: 1-211

  2. Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care 2019; 25 (2 Suppl): S23-34

  3. Porst M et al. Migraine and tension-type headache in Germany. Prevalence and disease severity from the BURDEN 2020 Burden of Disease Study. J Health Monit 2020; 5( Suppl 6): 2-24

  4. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain 2010; 11: 289-99

  5. Karsan N et al. Premonitory Symptoms of Migraine in Childhood and Adolescence. Curr Pain Headache Rep 2017; 21: 34

  6. Giffin NJ et al. The migraine postdrome: An electronic diary study. Neurology 2016; 87: 309-13

  7. Ashina M et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 2021; 397: 1496-504

  8. Kelman L. Pain characteristics of the acute migraine attack. Headache 2006; 46: 942-53

  9. Ashina M. Migraine. N Engl J Med 2020; 383: 1866-76

  10. Hougaard A et al. Provocation of migraine with aura using natural trigger factors. Neurology 2013; 80: 428-31

  11. Steiner TJ et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain 2019; 20: 57

  12. Lipton RB et al. Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache 2013; 53: 81-92

  13. Beh SC. Vestibular Migraine. Curr Neurol Neurosci Rep 2022; 22: 601-9

  14. Teggi R et al. Clinical features of headache in patients with diagnosis of definite vestibular migraine: The VM-Phenotypes Projects. Front Neurol 2018; 9: 395

  15. Cupini LM et al. Menstrual migraine: what it is and does it matter? J Neurol 2021; 268: 2355-63

  16. Diener HC et al. S1-Leitlinie "Therapie der Migräneattacke und Prophylaxe der Migräne". 2022

  17. Kropp P et al. Entspannungsverfahren und verhaltenstherapeutische Interventionen zur Behandlung der Migräne. Schmerz 2017; 31: 433-47

  18. Sprenger T et al. Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics 2018; 15: 313-23

  19. Katsarava Z et al. Poor medical care for people with migraine in Europe - evidence from the Eurolight study. J Headache Pain 2018; 19: 10

  20. Goßrau G et al. Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe. Nervenarzt 2023; 94: 306-17

  21. Holroyd KA et al. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 1991; 31: 333-40

  22. Jackson JL et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One 2019; 14: e0212785

  23. Centonze V et al. Efficacy and tolerability of flunarizine in the prophylaxis of migraine. Cephalalgia 1985; 5 (Suppl 2): 165-8

  24. Silberstein SD et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 170-80

  25. Jackson JL et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One 2015; 10: e0130733

  26. He A et al. Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. J Headache Pain 2017; 18: 26

  27. Jacobs H. A trial of opipramol in the treatment of migraine. J Neurol Neurosurg Psychiatry 1972; 35: 500-4

  28. Ozyalcin SN et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45: 144-52

  29. Aurora SK et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30: 793-803

  30. Ornello R et al. Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data. J Headache Pain 2020; 21: 40

  31. Cohen F et al. The arrival of anti-CGRP monoclonal antibodies in migraine. Neurotherapeutics 2022; 19: 922-30

Download references

Author information

Authors and Affiliations

  1. Neurologische Klinik und ­Poliklinik, LMU Klinikum Campus Großhadern, München, Deutschland

    Elizabeth George

  2. Neurologische Klinik / Oberbayer. Kopfschmerzzentrum, Klinikum Großhadern der LMU München, Marchioninistr. 15, 81377, München, Deutschland

    Andreas Straube

  3. - Neurolog. Klinik und Poliklinik -, Klinikum Großhadern d. LMU München, Marchioninistraße 15, 81377, München, Deutschland

    Katharina Kamm

Authors
  1. Elizabeth George
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Straube
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katharina Kamm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katharina Kamm.

Ethics declarations

Die Autorinnen und der Autor erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. E. G. und K. K. legen folgende potenzielle Interessenkonflikte offen: keine. A. S. hat Vortragshonorare von Novartis, Lilly, TEVA, Sanofi und Hormosan erhalten.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags durch zwei unabhängige Gutachten bestätigt wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

George, E., Straube, A. & Kamm, K. Migräne - Diagnostik und Prophylaxe. MMW - Fortschritte der Medizin 165, 52–58 (2023). https://doi.org/10.1007/s15006-023-2884-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-023-2884-1

Keywords:

Search

Navigation